Telbivudine for Chronic Hepatitis B. A Review

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)


Volume 14, 2 Issues, 2016


Download PDF Flyer




Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Telbivudine for Chronic Hepatitis B. A Review



Anti-Infective Agents, 7(4): 245-248.

Author(s): Emilio Palumbo.

Affiliation: Via dell'Arcangelo Michele 4, 71100 Foggia, Italy.

Abstract

Three hundred and fifty million people worldwide are estimated to be chronically infected with hepatitis B virus. 15%-40% of these subjects will develop cirrhosis, liver failure or hepatocellular carcinoma during their life. Approved drugs for chronic hepatitis B treatment include: standard interferon-alpha 2b, pegylated interferon-alpha 2a, lamivudine, adefovir dipivoxil, and entecavir. Unfortunately, these agents are not effective in all patients and are associated with distinct side effects. Interferons have numerous side effects and nucleoside or nucleotide analogues, which are well tolerated, need to be used for prolonged periods, even indefinitely. Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B and it was approved by the FDA in late 2006. In contrast to other nucleoside analogues, Telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity. Telbivudine has demonstrated potent activity against hepatitis B with a significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment, and adefovir. Telbivudine has been generally well tolerated, with a low adverse effect profile, and at its effective dose, no dose-limiting toxicity has been observed. The aim of this review is to evidence the pharmacodynamic and pharmacokinetic characteristics of this drug and to evaluate its efficacy and tolerance.

Keywords:

Telbivudine, pharmacodynamic, pharmacokinetic.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 7
Issue Number: 4
First Page: 245
Last Page: 248
Page Count: 4
DOI: 10.2174/187152108785908866
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science